MRSA: the first half century

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 1, 2012, Pages 4-11

  Moellering, Robert C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antibiotic resistance; Glycopeptides; Methicillin resistant S.aureus; Vancomycin

Indexed keywords

CEFTAROLINE; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DAPTOMYCIN; DICLOXACILLIN; FLUCLOXACILLIN; FUSIDIC ACID; LINEZOLID; METICILLIN; NAFCILLIN; OXACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; TELAVANCIN; TETRACYCLINE; TIGECYCLINE; VACCINE; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; DISEASE CARRIER; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; HUMAN; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PATHOGENESIS; PENICILLIN RESISTANCE; SURVIVAL; HISTORY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; PANDEMIC; REVIEW; STAPHYLOCOCCUS INFECTION;

DRUG RESISTANCE, MULTIPLE, BACTERIAL; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PANDEMICS; STAPHYLOCOCCAL INFECTIONS;

EID: 84859199622     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr437     Document Type: Article

References (79)

1. Jevons MP. Celbenin-resistant staphylococci. Br Med J 1961; 1: 124-5.
2. Moellering RC Jr. Past, present and future of antimicrobial agents. Am J Med 1995; 99 Suppl 6A: 11S-8S.
3. Majno G. The Healing Hand. Man and Wound in the Ancient World. Cambridge, MA: Harvard University Press, 1975.
4. Murray BE, Moellering RC Jr. Patterns and mechanisms of antibiotic resistance. Med Clin North Am 1978; 62: 899-923.
5. Moellering RC Jr. Vancomycin: a 50-year reassessment. Clin Infect Dis 2006; 42 Suppl 1: S3-4.
6. Tsubakishita S, Kuwahara-Arai K, Sasaki T et al. Origin and molecular evolution of the determinant of methicillin resistance in staphylococci. Antimicrob Agents Chemother 2010; 54: 4352-9.
7. Antignac A, Tomasz A. Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene. Antimicrob Agents Chemother 2009; 53: 435-41.
8. Couto I, de Lencastre H, Severina E et al. Ubiquitous presence of a mecA homologue in natural isolates of Staphylococcus sciuri. Microb Drug Resist 1996; 2: 377-91.
9. Enright MC, Robinson DA, Randle G et al. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci USA 2002; 99: 7687-92.
10. Johnson AP. Methicillin-resistant Staphylococcus aureus: the European landscape. J Antimicrob Chemother 2011; 66 Suppl 4: iv43-8.
11. Health Protection Agency. Voluntary Reporting of Staphylococcus aureus Bacteraemia in England, Wales and Northern Ireland, 2009. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1281952718651 (22 August 2011, date last accessed).
12. European Centre for Disease Prevention and Control. EARSS Annual Reports. http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Documents.aspx (22 August 2011, date last accessed).
13. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010; 23: 616-87.
14. Chua K, Laurent F, Coombs G et al. Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA-its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis 2011; 52: 99-114.
15. DeLeo FR, Otto M, Kreiswirth BN et al. Community-associated methicillin-resistant Staphylococcus aureus. Lancet 2010; 375: 1557-68.
16. Mera RM, Suaya JA, Madsen HA et al. Disproportionate increase from 2004-2008 in S. aureus associated US hospitalisation rates in children. In: Abstracts of the Twenty-first European Congress of Clinical Microbiology and Infectious Diseases/Twenty-seventh International Congress of Chemotherapy, Milan, Italy, 2011. Abstract P1219, p. 129. Basel: European Society of Clinical Microbiology and Infectious Diseases.
17. Lee SM, Ender M, Adhikari R et al. Fitness cost of staphylococcal cassette chromosome mec in methicillin-resistant Staphylococcus aureus by way of continuous culture. Antimicrob Agents Chemother 2007; 51: 1497-9.
18. Diep BA, Stone GG, Basuino L et al. The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus. J Infect Dis 2008; 197:1523-30.
19. Barbier F, Ruppe E, Hernandez D et al. Methicillin-resistant coagulase-negative staphylococci in the community: high homology of SCCmec IVa between Staphylococcus epidermidis and major clones of methicillin-resistant Staphylococcus aureus. J Infect Dis 2010; 202:270-81.
20. Robert J, Tristan A, Cavalie L et al. Panton-Valentine leukocidinpositive and toxic shock syndrome toxin 1-positive methicillin-resistant Staphylococcus aureus: a French multicenter prospective study in 2008. Antimicrob Agents Chemother 2011; 55: 1734-9.
21. Blanco R, Tristan A, Ezpeleta G et al. Molecular epidemiology of Panton-Valentine leukocidin-positive Staphylococcus aureus in Spain: emergence of the USA300 clone in an autochthonous population. J Clin Microbiol 2011; 49: 433-6.
22. Holzknecht BJ, Hardardottir H, Haraldsson G et al. Changing epidemiology of methicillin-resistant Staphylococcus aureus in Iceland from 2000 to 2008: a challenge to current guidelines. J Clin Microbiol 2010; 48: 4221-7.
23. Shaegren JN. Staphylococcus aureus. The persistent pathogen (first of two parts). N Engl J Med 1984; 310: 1368-73.
24. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997; 10: 505-20.
25. Mermel LA, Cartony JM, Covington P et al. Methicillin-resistant Staphylococcus aureus colonization at different body sites: a prospective, quantitative analysis. J Clin Microbiol 2011; 49: 1119-21.
26. Krebes J, Al-Ghusein H, Feasey N et al. Are nasal carriers of Staphylococcus aureus more likely to become colonized or infected with methicillin-resistant Staphylococcus aureus on admission to a hospital? J Clin Microbiol 2011; 49: 430-2.
27. Miller LG, Diep BA. Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; 46: 752-60.
28. Garcia-Alvarez L, Holden MTG, Lindsay H et al. Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study. Lancet 2011; 11: 595-603.
29. Hunter PA, Dawson S, French GL et al. Antimicrobial-resistant pathogens in animals and man: prescribing, practices and policies. J Antimicrob Chemother 2010; 65 Suppl 1: i3-17.
30. Moellering RC Jr, Abbott GF, Ferraro MJ. Case records of the Massachusetts General Hospital. Case 2-2011. A 30-year-old woman with shock after treatment of a furuncle. N Engl J Med 2011; 364:266-75.
31. Moellering RC Jr. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann Intern Med 2006; 144:368-70.
32. Lowy FD. How Staphylococcus aureus adapts to its host. N Engl J Med 2011; 364: 1987-90.
33. Li M, Cheung GYC, Hu J et al. Comparative analysis of virulence and toxin expression of global community-associated methicillin-resistant Staphylococcus aureus strains. J Infect Dis 2010; 202: 1866-76.
34. Bubeck Wardenburg J, Bae T, Otto M et al. Poring over pores: a-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 2007; 13: 1405-6.
35. Wang R, Braughton KR, Kretschmer D et al. Identification of novel cytolytic peptides as key virulence determinants for communityassociated MRSA. Nat Med 2007; 13: 1510-4.
36. Loughman JA, Fritz SA, Storch GA et al. Virulence gene expression in human community-acquired Staphylococcus aureus infection. J Infect Dis 2009; 199: 294-301.
37. Kennedy AD, Bubeck Wardenburg J, Gardner DJ et al. Targeting of a-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 2010; 202: 1050-8.
38. Kernodle DS. Expectations regarding vaccines and immune therapies directed against Staphylococcus aureus a-hemolysin. J Infect Dis 2011;203: 1692-3.
39. Han LL, McDougal LK, Gorwitz RJ et al. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol 2007; 45: 1350-2.
40. McDougal LK, Fosheim GE, Nicholson A et al. Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolatescausing invasive disease in the United States. Antimicrob Agents Chemother 2010; 54: 3804-11.
41. Moellering RC Jr. The specter of glycopeptide resistance: current trends and future considerations. Am J Med 1998; 104: 3S-6S.
42. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008; 46 Suppl 5: S360-7.
43. Courvalin P. Vancomycin resistance in Gram-positive cocci. Clin Infect Dis 2006; 42 Suppl 1: S25-34.
44. Howden BP, Ward PB, Charles PG et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-8.
45. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44: 1208-15.
46. van Hal SJ, Paterson DL. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011; 55: 405-10.
47. Peleg AY, Monga D, Pillai S et al. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J Infect Dis 2009; 199: 532-6.
48. Kennedy AD, Otto M, Braughton KR et al. Epidemic communityassociated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification. Proc Natl Acad Sci USA 2008; 105:1327-32.
49. Peleg AY, Cameron D, Ward D et al. A novel mechanism of reduced susceptibility to vancomycin in Staphylococcus aureus. In: Abstracts of the Twenty-first European Congress of Clinical Microbiology and Infectious Diseases/Twenty-seventh International Congress of Chemotherapy, Milan, Italy, 2011. Abstract P1050, p. 120. Basel:European Society of Clinical Microbiology and Infectious Diseases.
50. Schweizer ML, Furuno JP, Sakoulas G et al. Increased mortality with accessory gene regulator (agr) dysfunction in Staphylococcus aureus among bacteremic patients. Antimicrob Agents Chemother 2011; 55:1082-7.
51. Seidl K, Bayer AS, Fowler VG et al. Combinatorial phenotypic signatures distinguish persistent from resolving methicillin-resistant Staphylococcus aureus bacteremia isolates. Antimicrob Agents Chemother 2011; 55: 575-82.
52. Neoh HM, Cui L, Yuzawa H et al. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycinintermediate resistance. Antimicrob Agents Chemother 2008; 52: 45-53.
53. Cui L, Neoh HM, Shoji M et al. An rpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54: 5222-33.
54. Watanabe Y, Cui L, Katayama Y et al. Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus. J Clin Microbiol 2011; 49: 2680-4.
55. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674-80.
56. Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 2463-7.
57. Jang HC, Kim SH, Kim KH et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 2009; 49: 395-401.
58. Garrigos C, Murillo O, Euba G et al. Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54: 5251-6.
59. Vergidis P, Rouse MS, Euba G et al. Treatment with linezolid or vancomycin in combination with rifampin is effective in an animal model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis. Antimicrob Agents Chemother 2011; 55: 1182-6.
60. Cui L, Tominaga E, Neoh HM et al. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 1079-82.
61. Sakoulas G, Alder J, Thauvin-Eliopoulos C et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50:1581-5.
62. Kelley PG, Gao W, Ward PB et al. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother 2011; 66:1057-60.
63. Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 2137-45.
64. Yang SJ, Kreiswirth BN, Sakoulas G et al. Enhanced expression of dltABCD is associated with the development of nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis 2009; 200: 1916-20.
65. Peleg AY, McAlister A, Miyakis S et al. Genetic evolution of resistance to daptomycin in Staphylococcus aureus. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract C1-1434. American Society for Microbiology, Washington, DC, USA.
66. Dhand A, Bayer AS, Pogliano J et al. Use of antistaphylococcal b-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011; 53: 158-63.
67. Prystowsky J, Siddiqui F, Chosay J et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001; 45: 2154-6.
68. Marshall SH, Donskey CJ, Hutton-Thomas R et al. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 2002; 46: 3334-6.
69. Besier S, Ludwig A, Zander J et al. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness, costs, and cross-resistances. Antimicrob Agents Chemother 2008; 52: 1570-2.
70. Meka VG, Pillai SK, Sakoulas G et al. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 2004; 190: 311-7.
71. Meka VG, Gold HS, Cooke A et al. Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus. J Antimicrob Chemother 2004; 54: 818-20.
72. Long KS, Poehlsgaard J, Kehrenberg C et al. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob Agents Chemother 2006; 50: 2500-5.
73. Morales G, Picazo JJ, Baos E et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010; 50: 821-5.
74. Cercenado E, Cuevas O, Gama B et al. Present situation of antimicrobial resistance of Staphylococcus in Spain [2010]: seventh nationwide prevalence study and emerging resistance to linezolid. In: Abstracts of the Twenty-first European Congress of Clinical Microbiology and Infectious Diseases/Twenty-seventh International Congress of Chemotherapy, Milan, Italy, 2011. Abstract P1060, p. 120. Basel: European Society of Clinical Microbiology and Infectious Diseases.
75. Shinefield H, Black S, Fattom A et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002;346: 491-6.
76. Theuretzbacher U. Future antibiotics scenarios: is the tide starting to turn? Int J Antimicrob Agents 2009; 34: 15-20.
77. Moellering RC Jr. Discovering new antimicrobial agents. Int J Antimicrob Agents 2011; 37: 2-9.
78. Hackbarth CJ, Chen DZ, Lewis JG et al. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob Agents Chemother 2002; 46: 2752-64.
79. Novak R, Shlaes DM. The pleuromutilin antibiotics: a new class for human use. Curr Opin Investig Drugs 2010; 11: 182-91.